Home › Research › Mild cognitive impairment
Rates of clinical progression according to biological Alzheimer's disease stages
Lydia Trudel, Joseph Therriault, Arthur C. Macedo, Stijn Servaes, Seyyed Ali Hosseini, Gleb Bezgin, Nesrine Rahmouni, Tevy Chan et al.. Alzheimer s & Dementia, 2025-09-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Abstract INTRODUCTION Predicting the rate of cognitive decline and the likelihood of progression to dementia remains a critical unmet need in clinical settings. METHODS We assessed progression to mild cognitive impairment (MCI) and all‐cause dementia in 492 individuals from the TRIAD, ADNI, and HABS‐HD cohorts followed for an average of 2.49 years. Amyloid‐positive participants were staged according to the Alzheimer's Association biological staging framework (A+T 2 ‐/A+T 2MTL +/A+T 2MOD +/A+T 2HIGH +). RESULTS Cognitively unimpaired (CU) individuals in the A+T 2MTL +, A+T 2MOD +, and A+T 2HIGH + biological Alzheimer's disease (AD) stages were at significantly higher risk of clinical progression compared to non‐AD CU individuals. In individuals with MCI, advanced tau stage was associated with an 83% likelihood of developing dementia over 4 years. Biological AD staging demonstrated superior accuracy in predicting clinical progression compared to amyloid‐PET (positron emission tomography) status, tau‐PET status, and demographic information. All tau‐PET‐positive individuals showed a significantly faster rate of cognitive decline than non‐AD controls, with the A+T 2HIGH + stage showing the steepest rate of decline ( p < 0.001). DISCUSSION Our results highlight the prognostic value of biological AD staging. Highlights Cognitively unimpaired (CU) individuals in all tau‐PET (positron emission tomography)–positive biological Alzheimer's disease (AD) stages were at significantly higher risk of clinical progression compared to individuals without AD. In individuals with mild cognitive impairment (MCI), only the A+T 2HIGH + stage reached a point where 50% of individuals had progressed to all‐cause dementia, after 2.36 years. Biological AD staging demonstrated superior accuracy in predicting clinical progression to dementia compared to other PET biomarkers and demographic information. All tau‐PET‐positive individuals showed a significantly faster rate of cognitive decline than individuals without AD, with the A+T 2HIGH + stage showing the steepest rate of decline.
What this study adds
Evidence grade: Low
The record lists 492 participants. This study found that biological Alzheimer's disease staging, based on amyloid and tau PET, predicted progression to mild cognitive impairment and dementia better than amyloid PET status, tau PET status, or demographic information alone. It does not test a treatment or cure, but it suggests this staging may help identify who is at higher risk of decline.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Trudel, L., Therriault, J., Macedo, A. C., Servaes, S., Hosseini, S. A., Bezgin, G., et al. (2025). Rates of clinical progression according to biological Alzheimer's disease stages. Alzheimer s & Dementia. https://doi.org/10.1002/alz.70624
Vancouver
Trudel L, Therriault J, Macedo AC, Servaes S, Hosseini SA, Bezgin G, et al. Rates of clinical progression according to biological Alzheimer's disease stages. Alzheimer s & Dementia. 2025. doi:10.1002/alz.70624. PMID: 40951978.
BibTeX
@article{trudel2025-40951978,
author = {Trudel, Lydia and Therriault, Joseph and Macedo, Arthur C. and Servaes, Stijn and Hosseini, Seyyed Ali and Bezgin, Gleb and Rahmouni, Nesrine and Chan, Tevy and others},
title = {{Rates of clinical progression according to biological Alzheimer's disease stages}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz.70624},
pmid = {40951978},
url = {https://doi.org/10.1002/alz.70624}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- RESULTS Cognitively unimpaired (CU) individuals in the A+T 2MTL +, A+T 2MOD +, and A+T 2HIGH + biological Alzheimer's disease (AD) stages were at significantly higher risk of clinical progression compared to non‐AD CU individuals.
- In individuals with MCI, advanced tau stage was associated with an 83% likelihood of developing dementia over 4 years.
- Biological AD staging demonstrated superior accuracy in predicting clinical progression compared to amyloid‐PET (positron emission tomography) status, tau‐PET status, and demographic information.
- All tau‐PET‐positive individuals showed a significantly faster rate of cognitive decline than non‐AD controls, with the A+T 2HIGH + stage showing the steepest rate of decline ( p < 0.001).
- DISCUSSION Our results highlight the prognostic value of biological AD staging.
Why it matters
This study found that biological Alzheimer's disease staging, based on amyloid and tau PET, predicted progression to mild cognitive impairment and dementia better than amyloid PET status, tau PET status, or demographic information alone. It does not test a treatment or cure, but it suggests this staging may help identify who is at higher risk of decline.
Study details
- Participants492
- Evidence strengthLow
How this study scored 49/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 492 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 9 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 5.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 9 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Pedro Rosa‐Neto: h-index 89 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Southern California: institution h-index 1,521 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40951978) |
| Free to read | 2 / 2 | Free to read |
| Total | 49 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 30.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Mild cognitive impairment from nearby years
Also in Mild cognitive impairment
76 studies in the library are filed under Mild cognitive impairment with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Mild cognitive impairment hub.